| Name | Title | Contact Details |
|---|
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.
Neosho Memorial Regional Medical Center is a Chanute, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioMS Medical Corporation is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oxtel is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Project House is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.